Chemical compounds
This invention relates to non-steroidal compounds that are modulators of androgen receptor, and also to the methods for the making and use of such compounds.
1. A pharmaceutically acceptable salt of the compound:
2. A pharmaceutical composition comprising a pharmaceutically acceptable salt of the compound according to claim 1 and one or more pharmaceutically acceptable excipients.
3. A method of treating muscle wasting associated with chronic obstructive pulmonary disease (COPD), wherein said method comprises administering a pharmaceutically acceptable salt of the compound according to claim 1 to a human subject in need thereof.
4. A method of treating muscle wasting associated with chronic kidney disease (CKD), wherein said method comprises administering a pharmaceutically acceptable salt of the compound according to claim 1 to a human subject in need thereof.
5. A method of treating muscle wasting associated with chronic heart failure (CHF), wherein said method comprises administering a pharmaceutically acceptable salt of the compound according to claim 1 to a human subject in need thereof.
6. A method of treating urinary incontinence, wherein said method comprises administering a pharmaceutically acceptable salt of the compound according to claim 1 to a human subject in need thereof.
7. A method of accelerating hip fracture repair and healing, wherein said method comprises administering a pharmaceutically acceptable salt of the compound according to claim 1 to a human subject in need thereof.
8. The method according to claim 3 , wherein 0.1-50 mgs of a pharmaceutically acceptable salt of the compound is administered.
9. The method according to claim 4 , wherein 0.1-50 mgs of a pharmaceutically acceptable salt of the compound is administered.
10. The method according to claim 5 , wherein 0.1-50 mgs of a pharmaceutically acceptable salt of the compound is administered.
11. The method according to claim 6 , wherein 0.1-50 mgs of a pharmaceutically acceptable salt of the compound is administered.
12. The method according to claim 7 , wherein 0.1-50 mgs of a pharmaceutically acceptable salt of the compound is administered.